Brain effects of melanocortins.
The melanocortins (alpha, beta and gamma-melanocyte-stimulating hormones: MSHs; adrenocorticotrophic hormone: ACTH), a family of pro-opiomelanocortin (POMC)-derived peptides having in common the tetrapeptide sequence His-Phe-Arg-Trp, have progressively revealed an incredibly wide range of extra-hormonal effects, so to become one of the most promising source of innovative drugs for many, important and widespread pathological conditions. The discovery of their effects on some brain functions, independently made by William Ferrari and David De Wied about half a century ago, led to the formulation of the term "neuropeptide" at a time when no demonstration of the actual production of peptide molecules by neurons, in the brain, was still available, and there were no receptors characterized for these molecules. In the course of the subsequent decades it came out that melanocortins, besides inducing one of the most complex and bizarre behavioural syndromes (excessive grooming, crises of stretchings and yawnings, repeated episodes of spontaneous penile erection and ejaculation, increased sexual receptivity), play a key role in functions of fundamental physiological importance as well as impressive therapeutic effects in different pathological conditions. If serendipity had been an important determinant in the discovery of the above-mentioned first-noticed extra-hormonal effects of melanocortins, many of the subsequent discoveries in the pharmacology of these peptides (feeding inhibition, shock reversal, role in opiate tolerance/withdrawal, etc.) have been the result of a planned research, aimed at testing the "pro-nociceptive/anti-nociceptive homeostatic system" hypothesis. The discovery of melanocortin receptors, and the ensuing synthesis of selective ligands with agonist or antagonist activity, is generating completely innovative drugs for the treatment of a potentially very long list of important and widespread pathological conditions: sexual impotence, frigidity, overweight/obesity, anorexia, cachexia, haemorrhagic shock, other forms of shock, myocardial infarction, ischemia/reperfusion-induced brain damage, neuropathic pain, rheumathoid arthritis, inflammatory bowel disease, nerve injury, toxic neuropathies, diabetic neuropathy, etc. This review recalls the history of these researches and outlines the pharmacology of the extra-hormonal effects of melanocortins which are produced by an action at the brain level (or mainly at the brain level). In our opinion the picture is still incomplete, in spite of being already so incredibly vast and complex. So, for example, several of their effects and preliminary animal data suggest that melanocortins might be of concrete effectiveness in one of the areas of most increasing concern, i.e., that of neurodegenerative diseases.
Bertolini
Alfio
A
Division of Clinical Pharmacology, Department of Diagnostic Services, University of Modena and Reggio Emilia, Policlinico of Modena, Modena, Italy. bertolini.alfio@unimore.it
Tacchi
Raffaella
R
Vergoni
Anna Valeria
AV
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects*; D004435:Eating / Q000187:drug effects; D006120:Grooming / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D053486:Melanocortins / Q000494:pharmacology*; D008568:Memory / Q000187:drug effects; D010146:Pain / Q000503:physiopathology; D010410:Penile Erection / Q000187:drug effects; D017933:Peripheral Nervous System / Q000187:drug effects; D012725:Sexual Behavior / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects; D000521:alpha-MSH / Q000494:pharmacology
D053486:Melanocortins; D000521:alpha-MSH; D000324:Adrenocorticotropic Hormone